DAPASAN 10 TAB 10'S

About

Dapagliflozin 10mg, marketed as DAPASAN 10, is an oral antidiabetic medication belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. It works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion in the urine and subsequently lowering blood glucose levels. This mechanism is independent of insulin secretion, making it effective in various stages of type 2 diabetes.

Beyond its glycemic control effects, dapagliflozin has demonstrated significant cardiovascular and renal benefits. It reduces the risk of cardiovascular death, hospitalization for heart failure, and slows the progression of chronic kidney disease, offering comprehensive cardiorenal protection for patients with these conditions.

Uses

• Treatment of Type 2 Diabetes Mellitus
• Reduction of risk of cardiovascular death and hospitalization for heart failure in adults with heart failure
• Reduction of risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease
• Adjunct to diet and exercise to improve glycemic control

Directions For Use

Take one tablet orally once daily, with or without food, as directed by your healthcare provider. Do not crush or chew the tablet.

Benefits

• Effectively lowers blood glucose levels
• Reduces risk of cardiovascular death and heart failure hospitalization
• Slows the progression of chronic kidney disease
• Contributes to modest weight loss
• May help lower blood pressure
• Provides comprehensive cardiorenal protection

Side Effects

• Urinary tract infections (UTIs)
• Genital yeast infections (e.g., vulvovaginitis, balanitis)
• Increased urination frequency
• Thirst
• Nausea
• Dizziness or lightheadedness
• Back pain
• Flu-like symptoms
• Hypoglycemia (when used with insulin or sulfonylureas)
• Dehydration
• Diabetic ketoacidosis (rare but serious)
• Fournier's gangrene (very rare, severe perineal infection)

Safety Measures

• Alcohol - Alcohol consumption can increase the risk of hypoglycemia, especially when combined with other diabetes medications. It may also contribute to dehydration. Moderate intake is generally advised, and discuss with your doctor.
• Pregnancy - Dapagliflozin is not recommended during the second and third trimesters of pregnancy due to potential adverse effects on fetal kidney development. Use only if the potential benefit justifies the potential risk to the fetus.
• Breastfeeding - It is not recommended to use dapagliflozin while breastfeeding as it may pass into breast milk and potentially harm the infant. A decision should be made to discontinue nursing or discontinue the drug.
• Liver - Use with caution in patients with severe hepatic impairment as drug exposure may be increased. No dose adjustment is typically required for mild to moderate liver conditions, but monitoring is advisable.
• Kidney - Dose adjustments or discontinuation may be necessary based on estimated glomerular filtration rate (eGFR). Initiation is not recommended for patients with eGFR <25 mL/min/1.73m². Regular kidney function monitoring is crucial.
• Lung - There are no specific contraindications for dapagliflozin related to primary lung conditions. However, patients with severe respiratory illness should be monitored for dehydration or electrolyte imbalances, which could be exacerbated.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.